Docoh
Loading...

CFRX ContraFect

News

From Benzinga Pro
12 Health Care Stocks Moving In Friday's After-Market Session
7 Jan 22
Movers
Gainers ContraFect (NASDAQ:CFRX) stock moved upwards by 4.9% to $2.76 during Friday's after-market session. The company's market cap stands at $108.5 million.
12 Health Care Stocks Moving In Thursday's After-Market Session
6 Jan 22
Movers
Gainers ContraFect (NASDAQ:CFRX) stock increased by 4.9% to $2.76 during Thursday's after-market session. The company's market cap stands at $108.5 million.
ContraFect Announces Award From Cystic Fibrosis Foundation To Evaluate Exebacase As A Potential Treatment For Serious MRSA Lung Infections Associated With Cystic Fibrosis
6 Jan 22
General
ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical
From Benzinga's Global Small Cap Conference: ContraFect President & CEO, Roger J. Pomerantz, M.D., F.A.C.P. Begins Presenting
9 Dec 21
Exclusives, Interview
https://www.youtube.com/watch?v=XkOilNZqoEI
52 Biggest Movers From Yesterday
1 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
35 Stocks Moving In Tuesday's Mid-Day Session
30 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
CFRX: Direct Lytic Agents Show In Vitro Activity Against Gram-Negative Pathogens…
30 Nov 21
Penny Stocks
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT
ContraFect Q3 EPS $(0.13) Up From $(0.19) YoY
15 Nov 21
Earnings, News
ContraFect (NASDAQ:CFRX) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year.
ContraFect's New Data Presented At NACFC Demonstrate Potential Of Direct Lytic Agents To Treat Pulmonary Infections In Patients With Cystic Fibrosis
9 Nov 21
News, FDA
ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical